Text Size
275 studies found for:    biogen | biogen

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
biogen | biogen
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Intervention: Biological: Baminercept alfa (BG9924)
2 Completed Open-Label Safety Extension Study of Avonex
Condition: Multiple Sclerosis
Intervention: Drug: Interferon beta-1a (Avonex)
3 Terminated BG9924 in Combination With Methotrexate Extension of Study 104RA203
Condition: Rheumatoid Arthritis
Intervention: Drug: BG9924
4 Completed Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Patients
Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo;   Biological: baminercept alfa;   Biological: Baminercept alfa
5 Completed ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.
Condition: Multiple Sclerosis
Intervention:
6 Recruiting 215ON201 BIIB033 In Acute Optic Neuritis (AON)
Condition: Acute Optic Neuritis
Intervention: Biological: BIIB033
7 Recruiting ATLAS - Anti-Tweak in Lupus Nephritis Patients
Condition: Lupus Nephritis
Interventions: Drug: BIIB023;   Drug: Placebo
8 Completed
Has Results 		Natalizumab High Titer Immunogenicity and Safety
Condition: Multiple Sclerosis
Intervention: Drug: natalizumab
9 Completed A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
Condition: Relapsing Forms of Multiple Sclerosis
Interventions: Procedure: Plasma exchange;   Drug: natalizumab treatment
10 Recruiting Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010
Conditions: Painful Lumbar Radiculopathy;   Healthy
Interventions: Biological: BG00010;   Drug: Placebo
11 Recruiting An Efficacy and Safety Study of BG00012 in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: BG00012
12 Completed Open-Label Natalizumab Safety Extension Study
Condition: Multiple Sclerosis
Intervention: Drug: Natalizumab
13 Suspended Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma, Mixed;   Gliosarcoma
Intervention: Genetic: Interferon-beta
14 Completed Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Low-Grade
Intervention: Drug: ibritumomab tiuxetan (Zevalin®)
15 Completed Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: Interferon-beta-1a;   Drug: methylprednisolone
16 Completed Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy
Condition: Multiple Sclerosis
Intervention: Drug: low immunogenic interferon-beta-1a
17 Terminated Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Lumiliximab + FCR;   Drug: FCR
18 Withdrawn BIIB014 Phase 2a Monotherapy
Condition: Parkinson's Disease
Interventions: Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;   Drug: placebo
19 Completed BG9928 in Subjects With Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: BG9928
20 Terminated How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1a
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years